19:45 , Mar 31, 2017 |  BC Week In Review  |  Company News

Agalimmune, BioLineRx deal

BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares up front, plus undisclosed milestones. Agalimmune's lead compound AGI-134 is slated to begin clinical testing to treat solid tumors...
18:44 , Nov 4, 2016 |  BioCentury  |  Emerging Company Profile

Exploiting alpha-GAL

By coating tumor cells with a synthetic carbohydrate, Agalimmune Ltd. can enlist naturally circulating polyclonal antibodies to destroy primary solid tumor cells and stimulate an adaptive immune response against metastases. The newco’s Alphaject therapies are...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Kode Biotech, Agalimmune deal

Kode granted Agalimmune exclusive rights to use Function-Spacer-Lipid (FSL) cell surface membrane technology in the field of intratumoral injection to treat cancer. Kode is eligible to receive up to $31 million in development and sales...
07:00 , May 28, 2015 |  BC Innovations  |  Product R&D

Altermune's Alphamers

Altermune Technologies LLC is taking immunotherapy back to its day job of fighting infections with a new technology that coats bacteria with a sugar, and recruits circulating antibodies against the sugar to find and destroy...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Alpha-gal glycolipids: Phase I data

A Phase I trial in 9 patients with unresectable metastatic melanoma with >=1 resectable cutaneous, subcutaneous or palpable lymph node metastasis showed that 2 intratumoral injections of alpha-gal glycolipids given 4 weeks apart were well...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Agalimmune cancer news

Loxbridge Research LLP and Animatrix Capital LLP founded newco Agalimmune to develop immunotherapies to treat cancer, with a focus on solid tumors. Agalimmune has rights to Alphaject technology from the University of Massachusetts Medical Clinic....